Clinical trials: Coccidioides Immitis Infection
Toxoplasmosis, Toxoplasma Infections
Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)
Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii and transmitted to humans through the consumption of raw or undercooked infected meat and / or by poorly washed vegetables.
- Conditions
- Toxoplasmosis, Toxoplasma Infections, Toxoplasmosis, Congenital, Toxoplasmosis Recurrent
- Trial name
- TOXCELL (NCT04825600)
- Testing
- anti-Toxoplasma gondii IgG and IgM dosage, cellular test
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Rift Valley Fever
Rift Valley Fever in Kenya
The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya.
- Trial name
- NCT00287014
- Where
- Kenya
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00307021
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
- Trial name
- RVF (NCT00869713)
- Testing
- Inactivated, Dried (TSI-GSD 200), RVF Vaccine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Toxoplasmosis
Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
Pyrimethamine in combination with a sulphonamide is known to be effective in the treatment of toxoplasmosis. However, Pyrimethamine has not been approved by the Japanese regulatory body (Pharmaceutical and Medical Devices Agency…
- Trial name
- NCT03258762
- Testing
- Pyrimethamine, Calcium folinate
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RVF, Rift Valley Fever
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years
- Trial name
- NCT04672824
- Testing
- ChAdOx1 RVF, Saline
- Where
- Uganda
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
- Trial name
- RVF (NCT00584194)
- Testing
- TSI-GSD 200 RVF Vaccine
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Congenital Toxoplasmosis
New Diagnostic Approach for Congenital Toxoplasmosis
Caused by Toxoplasma gondii, toxoplasmosis is mostly asymptomatic except in immunocompromised individuals and infants infected in utero.
- Trial name
- TOXODIAG (NCT03385499)
- Testing
- blood additional samples
- Where
- 3 sites in France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cryptosporidiosis
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients.
- Trial name
- CRYPTONITE (NCT07249463)
- Testing
- Cryptosporidium parvum oocysts (ABO809), EDI048
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rift Valley Fever, Hemorrhagic Fevers, Viral
RVF and Other Emerging Infectious Diseases in East and Central Africa
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one…
- Trial name
- NCT05139524
- Testing
- Evidence of past or recent RVF exposure
- Where
- 10 sites in Democratic Republic of the Congo, Kenya and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Washington State University
Cryptosporidium; Diarrhea, Cryptosporidiosis
Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya
The aim of the study is to examine the efficacy of ceramic water filters to reduce the burden of waterborne diarrheal illness among infants in selected villages in Kenya.
- Conditions
- Cryptosporidium; Diarrhea, Cryptosporidiosis, Communicable Diseases, Diarrheal Disease
- Trial name
- NCT01695304
- Testing
- Ceramic water filter
- Where
- Kenya
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Coccidioidomycosis
Safety and Pharmacokinetics of VT-1598
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in healthy adult subjects ages 18 - 45 years inclusive. It is designed to evaluate the safety and PK of single oral doses of VT-1598.
- Trial name
- NCT04208321
- Testing
- VT-1598
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Malnutrition
Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events
The purpose of this study is to understand how breast milk may protect infants from infection and promote favorable immunological, growth and development outcomes.
- Conditions
- HIV, Malnutrition, Cryptosporidiosis
- Trial name
- NCT01699841
- Where
- Tanzania
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Cornell University
Rift Valley Fever
Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
The goal of this clinical trial is to learn if ChAdOx1 RVF, a candidate vaccine against RVF, provides an adequate immune response and determine its safety among Kenyan adults.
- Trial name
- RVF003 (NCT06799234)
- Testing
- ChAdOx1 RVF, Rabies Vaccine
- Where
- Kenya
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Cryptosporidiosis
Cryptosporidium Species in Sohag Governorate
Cryptosporidium species are increasingly recognized as important enteric pathogens that infect a broad range of hosts including human, domestic and wild animals worldwide, causing asymptomatic or mild-to-severe gastrointestinal…
- Trial name
- NCT05208970
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
Rift Valley Fever
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy…
- Trial name
- NCT06925919
- Testing
- IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IDBiologics, Inc.
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Rift Valley Fever
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
Phase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF
- Trial name
- NCT04754776
- Testing
- ChAdOx1 RVF
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Coccidioidomycosis, Rheumatoid Arthritis
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.
- Trial name
- NCT00796809
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- University of Arizona